Prokidney Corp. PROK
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2021 · data as of November 13, 2026
Prokidney Corp. (PROK) is a healthcare company listed in the US with a market value of about $417M. In the twelve months to September 30, 2026 it had revenue of $775000 and net income of -$103M, a net margin of -13326.7%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -155%.
About Prokidney
Prokidney is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2021. It was profitable in 0 of the last 6 years in our data. Its share count rose by 549% over three years (dilution for shareholders). It spends 12780% of revenue on research and development.
Score: 1.0 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $775000 | $893000 | $76000 | $0 | $0 | — | — |
| Net income | -$103M | -$69M | -$61M | -$35M | -$148M | -$55M | -$27M |
| Free cash flow | -$168M | -$135M | -$156M | -$124M | -$79M | -$55M | -$31M |
| EPS (diluted) | $-0.26 | $-0.17 | — | — | $-0.23 | — | — |
| Net margin | -13326.7% | -7725.2% | -80507.9% | — | — | — | — |
| ROIC | — | — | — | — | — | -154.7% | -271.6% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 5 analysts is $6.50, 522% above the current price; targets range from $1.00 to $12.00; the consensus rating is “Buy”; expected EPS is $-0.65 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Prokidney pay a dividend?
Not currently.
Is Prokidney a good stock to buy?
We do not give buy or sell advice. Prokidney scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.